Investment Overview
American Healthcare Capital is proud to exclusively present an opportunity to acquire a majority interest in a profitable, rapidly growing prosthetics and orthotics platform operating in the Southeastern United States. The Company provides custom prosthetic, orthotic, and advanced bionic solutions through a patient-centric, technology-enabled clinical model.
The business has demonstrated strong revenue growth, meaningful margin expansion, and scalable unit economics, positioning it as an attractive platform investment within a resilient healthcare sub-sector benefiting from long-term demographic and technological tailwinds.
Business Highlights
- Customized prosthetic and orthotic solutions, including advanced bionic and myoelectric systems
- High-touch clinical model focused on outcomes, mobility, and patient independence
- Strong brand recognition with a mission-driven, empathetic care philosophy
- Diversified referral base including physicians, rehabilitation centers, and healthcare providers
- Asset-light operating structure with scalable infrastructure
- Favorable industry dynamics driven by aging population and increased demand for mobility solutions
Financial Summary
Gross revenue increased meaningfully from $1.0 million in 2024 to $1.4 million in 2025, reflecting strong organic growth and improved operating scale. This momentum is expected to continue in 2026, with projected revenue of $1.75 million, representing a two-year compound growth profile that is both consistent and sustainable.
Adjusted EBITDA expanded at an even faster pace, rising from approximately $198,000 in 2024 (19%) to $405,000 in 2025 (29%). The improvement reflects both revenue growth and enhanced cost efficiency. For 2026, adjusted EBITDA is projected at $508,000, maintaining a 29% margin, which indicates that profitability gains are being preserved as the business scales rather than eroding with growth.
Key Financial Takeaways:
- ~39% revenue growth from 2024 to 2025
- Adjusted EBITDA more than doubled year-over-year
- Significant margin expansion driven by operating leverage
- Consistent profitability with clear visibility into continued growth
- Growth Opportunities
- Geographic expansion through de-novo locations and tuck-in acquisitions
- Increased penetration of higher-margin advanced prosthetic and bionic solutions
- Deeper referral relationships with hospitals, rehabilitation networks, and VA systems
- Institutional support to professionalize operations and accelerate scale
- Platform consolidation opportunity within a fragmented prosthetics & orthotics market
Key Valuation Drivers and Ideal Buyer Profile
The Company’s valuation is underpinned by strong historical growth, expanding margins, and a highly scalable operating model, further differentiated by its position as a veteran- and woman-owned healthcare platform in a resilient, growing sector.
A key value driver is the founders’ commitment to remain actively involved post-transaction and to roll over a meaningful equity stake, ensuring operational continuity and alignment with a partner’s growth objectives. A structured earn-out is also contemplated to bridge valuation expectations and directly link additional consideration to future performance, supporting a shared goal of scaling the business and achieving a targeted liquidity event in approximately five years.
The Company is well suited for healthcare-focused private equity firms, strategic prosthetics and orthotics platforms, family offices seeking scalable healthcare investments, and investors pursuing platform build-and-expand strategies.
Transaction Overview & Asking Price
Target Valuation: Founders are open to majority equity at fair market valuation from a strategic or a capital partner that can help them grow and scale to the next level, reflecting the Company’s strong growth trajectory, profitability, and future potential.
Transaction Structure: Majority recapitalization with seller rollover equity.
Consideration: Total consideration may include a combination of cash at closing, rollover equity, and a performance-based earn-out tied to future growth.
Exclusions: Cash, working capital, accounts receivable, and real property.
